Skip to main content
Clinical Trials/NCT05841199
NCT05841199
Recruiting
Not Applicable

Coronary Epicardial and Microcirculatory Determinants of Ventricular Tachycardia Tolerability

Imperial College London1 site in 1 country70 target enrollmentAugust 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ventricular Tachycardia
Sponsor
Imperial College London
Enrollment
70
Locations
1
Primary Endpoint
Change in blood pressure in participants before and after PCI
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this observational study is to learn about the factors which determine how well ventricular tachycardia (VT) is tolerated. The main questions it aims to answer are:

  1. What impact does coronary artery disease have on the ability for a patient to tolerate VT?
  2. Does treatment of coronary artery disease with stents improve the tolerability of VT?

Participants who are undergoing a clinically indicated coronary angiogram or coronary angioplasty procedure will have measurements of blood pressure, coronary pressure and coronary flow made during pacing at a range of heart rates.

Detailed Description

Ventricular tachycardia (VT) is a common and life-threatening arrhythmia that occurs in people with heart problems. Some patients who develop this arrhythmia remain very stable with very little symptoms while others become unstable with low blood pressure or even sudden death. It is not known why some people tolerate the arrhythmia well and others do not. If VT is not tolerated then current practice is to offer an implantable cardioverter defibrillator (ICD) which can deliver a shock to the heart if dangerous heart rhythms are detected. While shocks can be life-saving, they are also harmful, including causing psychological distress. ICDs also frequently deliver shocks when they are not needed. If research could identify which factors predispose a person to be stable or unstable in VT, this would allow doctors to help them in a range of ways. One way would be to treat patients to improve the tolerance of VT, so avoiding the need for an ICD. Another would be to assess the the risk of instability and so allow a patient-centred decision on whether an ICD is needed. In this study the investigators plan to recruit patients who are referred for a coronary angiogram. During the angiogram, the investigators will stimulate the heart at a range of fast heart rates and measure their blood pressure and flow in their coronary arteries. In patients who undergo stenting for a coronary stenosis, the investigators will also make these measurements after stenting so they can see if there is any difference. By recruiting a range of different cardiology patients, the investigators will be able to assess which factors contribute to stability during VT.

Registry
clinicaltrials.gov
Start Date
August 1, 2023
End Date
February 2, 2026
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Able to give valid consent
  • Referred for coronary angiography or coronary angioplasty
  • Suitable for percutaneous physiological interrogation and PCI when clinically indicated

Exclusion Criteria

  • Unable to give valid consent
  • Pregnant or breastfeeding women
  • Unstable coronary artery disease (acute coronary syndrome)
  • Severe multivessel coronary artery disease suitable for coronary artery bypass grafting
  • Severe heart valve disease
  • Severe (NYHA IV) heart failure

Outcomes

Primary Outcomes

Change in blood pressure in participants before and after PCI

Time Frame: At baseline and during simulated VT, immediately before PCI and after PCI

Change in coronary flow in participants with different levels of coronary microvascular function.

Time Frame: At baseline and during simulated VT

Change in coronary flow in participants immediately before and after PCI

Time Frame: At baseline and during simulated VT, immediately before PCI and after PCI

Change in blood pressure in participants with different levels of coronary microvascular function.

Time Frame: At baseline and during simulated VT

Secondary Outcomes

  • Change in blood pressure in participants with different levels of left ventricular function(At baseline and during simulated VT)
  • Change in coronary flow in participants with different levels of left ventricular function(At baseline and during simulated VT)

Study Sites (1)

Loading locations...

Similar Trials